OtherVC-backedSeries E
Hong Kong, Hong Kong · Founded 2014
Insilico Medicine
Generative AI for drug discovery.
About Insilico Medicine
End-to-end AI platform discovering and designing drug candidates. First fully AI-designed drug (INS018_055) reached Phase II for IPF.
Company facts
- Category
- Other
- Funding stage
- Series E
- Total raised
- $401M+
- Founded
- 2014
- Team size
- 201-500
- HQ
- Hong Kong
- Country
- Hong Kong
- Website
- insilico.com
Founders of Insilico Medicine
- Alex Zhavoronkov
Investors backing Insilico Medicine
- Sequoia China
- Warburg Pincus
- Pavilion Capital
Frequently asked questions
What does Insilico Medicine do?
End-to-end AI platform discovering and designing drug candidates. First fully AI-designed drug (INS018_055) reached Phase II for IPF.
Where is Insilico Medicine based?
Insilico Medicine is based in Hong Kong, Hong Kong.
When was Insilico Medicine founded?
Insilico Medicine was founded in 2014.
How much has Insilico Medicine raised?
Insilico Medicine has raised $401M+ in their Series E round.
Who founded Insilico Medicine?
Insilico Medicine was founded by Alex Zhavoronkov.
Who has invested in Insilico Medicine?
Insilico Medicine is backed by Sequoia China, Warburg Pincus, Pavilion Capital.